ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zanzalintinib

Also written as “Zanzalintinib” and “XL092”.

Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Adenoma, Islet Cell, led by 3 companies.

Drug pageZanzalintinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 16, 202217 company-led studies, 15 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixis1312 open or runningphase 3since Jun 16, 2022Feb 15, 2019Dec 15, 2026phase 3 · NCT05678673
Merckits history only33 open or runningphase 3since Nov 7, 2025Jun 25, 2025Nov 27, 2030phase 3 · NCT07489495
Hoffmann-La Rocheits history only10 open or runningphase 2since Nov 7, 2017Nov 7, 2017none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Exelixis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 15, 2019First study: phase 1 study in NeoplasmsFirst studyNCT03845166 · 325 enrolled · United States, Australia, Belgium and more
  2. Dec 15, 2021Phase 1 study in Carcinoma, Renal CellNCT05176483 · 1,394 planned · United States, Australia, Austria and more
  3. Jun 16, 2022Phase 3 study in Colorectal NeoplasmsNCT05425940 · 901 enrolled · United States, Australia, Belgium and more
  4. Jul 21, 2022Named zanzalintinibINNProposed as its International Nonproprietary Name in WHO's List 127 · before, XL092
  5. Dec 23, 2022Phase 3 study in Non-Clear Cell Renal Cell CarcinomaNCT05678673 · 317 enrolled · United States, Argentina, Australia and more
  6. Oct 9, 2023Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06082167 · 600 enrolled · United States, Argentina, Australia and more
  7. Dec 19, 2023Phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsNCT06191796 · 25 enrolled · United States
  8. Apr 17, 2025Phase 3 study in Adenoma, Islet CellNCT06943755 · 440 planned · United States, Australia, Austria and more
  9. Apr 30, 2025Phase 1 study in Hepatic ImpairmentNCT06962332 · 20 planned · United States
  10. Feb 19, 2026Phase 2 study in MeningiomaNCT07428616 · 100 planned · United States
  11. May 27, 2026Phase 3 study in NeoplasmsNCT07620574 · 5,000 planned · United States
  12. Aug 3, 2026Phase 3 study in Colorectal NeoplasmsNCT07750158 · 600 planned · United States
  13. Aug 12, 2026Phase 1 study in NeoplasmsNCT07773454 · 18 planned
  14. Sep 22, 2026Phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)NCT07845786 · 60 planned · United States

Ahead

  1. Dec 15, 2026Primary completion: phase 3 study in Non-Clear Cell Renal Cell CarcinomaNCT05678673
  2. Jan 31, 2027Primary completion: phase 1 study in Carcinoma, Renal CellNCT05176483
  3. Feb 29, 2028Primary completion: phase 2 study in MeningiomaNCT07428616
  4. Jun 15, 2028Primary completion: phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)NCT07845786

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, ”NCIt, by rule

Studies

All 13 Exelixis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07845786Squamous Non-Small Cell Lung Cancer (NSCLC) · United States2RecruitingJun 15, 202860
NCT07773454Neoplasms1Not yet recruitingJul 31, 202818
NCT07750158Colorectal Neoplasms · United States3RecruitingApr 5, 2030600
NCT07620574Neoplasms · United States3By invitationMay 31, 20305,000
NCT07428616Meningioma · United States2RecruitingFeb 29, 2028100
NCT06962332Hepatic Impairment · United States1RecruitingDec 202520
NCT06943755Adenoma, Islet Cell · United States, Australia, Austria and more3RecruitingJun 30, 2029440
NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States1TerminatedMay 12, 202525
NCT06082167Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3Active, not recruitingAug 2028600
NCT05678673Non-Clear Cell Renal Cell Carcinoma · United States, Argentina, Australia and more3Active, not recruitingDec 15, 2026317
NCT05425940Colorectal Neoplasms · United States, Australia, Belgium and more3Active, not recruitingJun 16, 2026901
NCT05176483Carcinoma, Renal Cell · United States, Australia, Austria and more1RecruitingJan 31, 20271,394
NCT03845166Neoplasms · United States, Australia, Belgium and more1Active, not recruitingAug 31, 2026325

How it is read

Names in the registry

  • “Zanzalintinib”, 12 entries
  • “XL092”, 4 entries
  • “zanzalintinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.